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Sreekumar Sundara-Rajan5, Matthew P. Humphries5, Maddalena Barba3,6, Valerie Speirs5, 
Ruggero De Maria7,† & Marcello Maugeri-Saccà3,6,†
Male breast cancer (MBC) is a rare hormone-driven disease often associated with obesity. HMG-
CoAR is the central enzyme of the mevalonate pathway, a molecular route deputed to produce 
cholesterol and steroid-based hormones. HMG-CoAR regulates the oncogenic Hippo transducers 
TAZ/YAP whose expression was previously associated with shorter survival in MBC. 225 MBC samples 
were immunostained for HMG-CoAR and 124 were considered eligible for exploring its relationship 
with hormone receptors (ER, PgR, AR), Hippo transducers and survival outcomes. HMG-CoAR was 
positively associated with the expression of hormone receptors (ER, PgR, AR) and Hippo transducers. 
Overall survival was longer in patients with HMG-CoAR-positive tumors compared with their negative 
counterparts (p = 0.031). Five- and 10-year survival outcomes were better in patients whose tumors 
expressed HMG-CoAR (p = 0.044 and p = 0.043). Uni- and multivariate analyses for 10-year survival 
suggested that HMG-CoAR expression is a protective factor (HR 0.50, 95% CI: 0.25–0.99, p = 0.048 and 
HR 0.53, 95% CI: 0.26–1.07, p = 0.078). Results were confirmed in a sensitivity analysis by excluding 
uncommon histotypes (multivariate Cox: HR 0.45, 95% CI: 0.21–0.97, p = 0.043). A positive relationship 
emerged between HMG-CoAR, hormone receptors and TAZ/YAP, suggesting a connection between the 
mevalonate pathway, the hormonal milieu and Hippo in MBC. Moreover, HMG-CoAR expression may be 
a favorable prognostic indicator.
Male breast cancer (MBC) is a rare disease1, even though its incidence has increased over the past decades2,3. 
Similar to other uncommon diseases, its biology is understudied despite recent efforts toward obtaining informa-
tion on genomic alterations and deregulated pathways4–10. An established concept is the hormone-driven nature 
of the disease. First, a number of conditions that alter the hormonal milieu, such as aging, obesity, liver diseases, 
Klinefelter’s syndrome and testicular disorders, are linked to MBC1,11. Second, steroid receptors, such as the estro-
gen receptor (ER), progesterone receptor (PgR) and androgen receptor (AR), are often expressed in MBC, even 
more frequently than in female breast cancer (FBC)12,13. Consistently, hormone therapies are central in the med-
ical management of MBC patients14–16.
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3-Hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), the molecular target of statins, 
acts as the rate-limiting enzyme in the mevalonate pathway, a metabolic route that leads to the production of 
steroid-based hormones, cholesterol, and non-sterol isoprenoids17. Considering the close connection between the 
mevalonate pathway and hormonal stimuli, it is not surprising that HMG-CoAR expression was associated with 
ER positivity, anthropometric factors (e.g. obesity), increased efficacy of adjuvant tamoxifen and better survival 
outcomes in FBC18–20.
Nevertheless, the contribution of intratumoral HMG-CoAR to the biology of cancer is more complex, as 
preclinical studies uncovered a number of aberrantly regulated processes requiring the activity of the enzyme21. 
Key intermediates of the mevalonate pathway, namely farnesyl pyrophosphate (FPP) and geranylgeranyl pyroph-
osphate (GGPP), are central metabolites in the process of prenylation21. This post-translational process facilities 
correct membrane anchoring of a number of molecules, even including signal transduction proteins involved 
in oncogenic signals, such as the small GTPases Ras, Rab, Rho. Consistently with the biological importance of 
protein prenylation in cancer, farnesyltransferase inhibitors were developed, chiefly as Ras-targeting agents, albeit 
the results reported so far have been disappointing21.
A recently described function of HMG-CoAR refers to its control on the Hippo transducers TAZ/YAP22,23, two 
closely related oncoproteins acting downstream in the evolutionary conserved Hippo pathway24. According to 
this model, GGPP favors TAZ/YAP nuclear accumulation and transcription of target genes by promoting mem-
brane localization of Rho GTPases22. Importantly, activation of Hippo transducers has increasingly been linked to 
breast cancer stem cell (CSC) function25–28, and CSC pathway analysis has been advocated as a powerful strategy 
for developing novel prognostic/predictive markers. Consistently, retrospective clinical studies raised the hypoth-
esis that Hippo-related biomarkers may predict poorer outcomes in FBC29–31, and we have already provided hints 
that expression of TAZ/YAP and their target Connective Tissue Growth Factor (CTGF) is associated with inferior 
survival compared to TAZ/CTGF and YAP/CTGF negative MBC patients32.
Prompted by the potential “Janus-faced” role of HMG-CoAR, namely i) its connection with hormone recep-
tors and favorable clinical outcomes observed in FBC18–20 and, on the other side, ii) the positive control that 
HMG-CoAR operates on a variety of oncogenic proteins, even including pathways involved in CSC fate22, we 
herein investigated HMG-CoAR expression in a large series of MBC samples. Our goals were the following: i) 
describing its expression pattern, ii) evaluating its association with hormone receptors (ER, PgR, AR) and Hippo 
transducers (TAZ/YAP plus their target CTGF), and iii) analyzing the impact of HMG-CoAR expression on 
survival outcomes.
Results
Relationship between HMG-CoAR, hormone receptors and Hippo transducers. For this retro-
spective study, 255 MBC samples were screened for the expression of HMG-CoAR. One hundred twenty four 
patients (124) were included on the basis of the eligibility criteria described in the paragraph addressing Materials 
and Methods. One hundred thirty one (131) patients were excluded for the following reasons: missing (N = 100) 
or ambiguous (N = 7) data on overall survival (OS), missing data on HMG-CoAR status (N = 17), missing data 
on AR status (N = 6), missing data on PgR status (N = 1).
Eligible patients were diagnosed with breast cancer in the time frame between 1983 and 2009. Baseline char-
acteristics of these patients are summarized in Table 1. Median age at diagnosis was 67.5 years. One hundred 
Characteristics N (%)
Age at diagnosisα Median (min-max) [IQ range] 67.5 (34–86) [59–75]
*Histology IDC/ILC 104 (83.9)
Other** 20 (16.1)
*Grade G1-2 65 (52.4)
G3 59 (47.6)
Nodal status Negative 36 (29.0)
Positive 55 (44.4)
Unknown 33 (26.6)
Hormone Receptors ER+/PgR+ 105 (84.7)
Other• 19 (15.3)
*Ki-67 Low 72 (58.1)
High 52 (41.9)
HMG-CoAR Neg 43 (34.7)
Pos 81 (65.3)
Table 1.  Baseline characteristics of MBC patients included in this study (N = 124). α Computed in 106 
patients. *Variables with missing values. The number of cases with missing values by variable of interest was 
as follows: histology: 1/124, tumor grade: 2/124, and Ki-67 levels: 4/124. The missing values were replaced 
using the random hot deck method (Materials and Methods). **Other: Adenocarcinoma (N = 3), Intraductal 
Papillary Carcinoma (N = 2), Papillary Carcinoma (N = 6), Mucinous carcinoma (N = 2), Mixed (N = 4), 
Medullary (N = 1), Micropapillary (N = 1), Tubular (N = 1). • Other: ER+/PgR− (N = 16), ER−/PgR− (N = 3). 
Abbreviations: IDC: Invasive Ductal Carcinoma, ILC: Invasive Lobular Carcinoma.
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four patients (83.9%) were diagnosed with invasive ductal carcinoma (IDC) or invasive lobular carcinoma (ILC). 
Nodal status was described as positive in 55 patients (44.4%). 105 (84.7%) men had a ER+ /PgR+ disease and 
Ki-67 was rated as low in 72 (58.1%) cases. When evaluated by HMG-CoAR status, 43 (34.7) patients tested 
negative. The formalin-fixed paraffin-embedded (FFPE) blocks of MBC patients were collected in Europe and 
Canada13. Median follow up was 183 months (95% CI 91.4–274.7). Representative immunohistochemical staining 
is presented in Fig. 1. When considered as a categorical variable, HMG-CoAR expression was positively associ-
ated with the expression of ER, PgR and AR (p = 0.040, p = 0.021 and p = 0.009, respectively as shown in Fig. 2, 
panel A). Moreover, we observed a significant positive correlation between HMG-CoAR and ER, PgR and AR 
(Fig. 2, panel B). Interestingly, HMG-CoAR was also positively associated with the TAZ/CTGF and YAP/CTGF 
phenotypes (p = 0.007 and p = 0.004, respectively; Fig. 2, panel A), and positively correlated with TAZ, YAP and 
CTGF (Fig. 2, panel B). Overall, our data seem to provide evidence in support of a link between the expression 
Figure 1. Representative examples of immunohistochemical expression of HMG-CoAR in four male breast 
cancer patients. Two exemplificative cases (A,B) of positive HMG-CoAR expression are shown, documenting 
homogenous cytoplasmic positivity in all the three TMA cores pertinent to each case (a–f). Two negative cases 
(C,D) are also shown (g–i; j–l). Scale bar 30 μ m.
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of HMG-CoAR and that of both hormone receptors and central actors of the Hippo signaling pathway in MBC. 
We did not observe any significant association between HMG-CoAR and histology, Ki-67 levels, tumor grade 
and nodal status (data available upon request). Similarly, the median age and range in HMG-CoAR positive and 
negative subjects were comparable (69 (34–84) and 66 (34–86) years, respectively).
Prognostic Significance of HMG-CoAR expression. We next investigated the impact of HMG-CoAR 
on survival outcomes. OS (defined in the Materials and Methods section) was longer in patients whose tumors 
expressed HMG-CoAR compared with their negative counterparts (Tarone-Ware p = 0.031) (Fig. 3), as well as 
5- and 10-year survival (log rank p = 0.044 and p = 0.043, respectively, Fig. 3). The univariate Cox regression 
analysis carried out for identifying variables impacting 10-year survival, presented in Table 2, confirmed the 
protective role of HMG-CoAR (HR 0.50, 95% CI: 0.25–0.99, p = 0.048), which was the only variable significantly 
Figure 2. Relationship between HMG-CoAR, hormone receptors and the TAZ/CTGF and YAP/CTGF 
phenotypes. Associations are shown in panel (A) correlations in panel (B).
Figure 3. Kaplan-Meier survival curves comparing HMG-CoAR-positive and HMG-CoAR-negative cases 
(N = 124). 
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associated with the investigated outcome. Nevertheless, we verified the role of HMG-CoAR in a multivariate 
model by adjusting for other plausible variables (histology, grade, hormone receptor status, and Ki-67 levels), 
albeit they did not test significant at the univariate assessment. As shown in Table 2, a non-significant reduction 
in overall mortality was observed for patients with HMG-CoAR-positive tumors comparing with those whose 
tumors were HMG-CoAR-negative (HR 0.53, 95% CI: 0.26–1.07, p = 0.078). In a sensitivity analysis carried out 
by excluding uncommon histotypes (N = 20), HMG-CoAR was fully significant in the multivariate Cox model 
(HR 0.45, 95% CI: 0.21–0.97, p = 0.043), as reported in Table 3. Interestingly, in subgroup analysis HMG-CoAR 
positivity was a protective factor in patients whose tumors harbored the TAZ/CTGF and YAP/CTGF pheno-
types (HR and 95% CI were 0.31 (0.10–0.96) and 0.30 (0.11–0.88), respectively) (Fig. 4). Finally, in the subset of 
patients with available information on nodal involvement (N = 91), HMG-CoAR expression was associated with 
better survival outcomes in patients with node-positive disease, with HR and 95% CI being 0.29 (0.10–0.83), 0.23 
(0.06–0.97) and 0.27 (0.09–0.86) for OS, 5- and 10-year survival, respectively (Fig. 5).
Discussion
In the present study, we retrospectively investigated the expression of HMG-CoAR in a large cohort of MBC 
patients with available hormone receptor status and survival data. This cohort was previously analyzed for the 
Univariate Cox Multivariate Cox§
HR (95% CI) p-value *HR (95% CI) p-value
Histology IDC/ILC vs. other 1.03 (0.40–2.66) 0.955 0.92 (0.35–2.42) 0.871
Grade G3 vs. G1-2 1.53 (0.77–3.03) 0.225 1.41 (0.68–2.94) 0.356
Hormone Receptors ER+/PgR+ vs. other 0.70 (0.30–1.62) 0.406 0.87 (0.37–2.08) 0.758
Ki-67 High vs. Low 1.10 (0.55–2.21) 0.777 1.01 (0.49–2.08) 0.985
HMG-CoAR Pos vs. Neg 0.50 (0.25–0.99) 0.048 0.53 (0.26–1.07) 0.078
Table 2.  Univariate and multivariate Cox regression analysis for 10-year survival (N = 124). *HR and 
95% CI were calculated for each variable, mutually adjusted for all other covariates. §Adjusted for: Histology, 
Grade, Hormone Receptors, and Ki-67.
Univariate Cox regression model Multivariate Cox regression model§
HR (95% CI) p-value *HR (95% CI) p-value
Grade G3 vs. G1-2 1.44 (0.68–3.05) 0.336 1.33 (0.60–2.96) 0.487
Hormone Receptors ER+/PgR+ vs. other 0.56 (0.24–1.32) 0.184 0.72 (0.29–1.78) 0.474
Ki-67 High vs. Low 1.08 (0.51–2.28) 0.843 1.03 (0.46–2.30) 0.949
HMG-CoAR Pos vs. Neg 0.42 (0.20–0.89) 0.023 0.45 (0.21–0.97) 0.043
Table 3.  Univariate and multivariate Cox regression models for 10-year survival in IDC/ILC patients 
(N = 104). *HR and 95% CI were calculated for each variable, mutually adjusted for all other covariates. 
§Adjusted for: Grade, Hormone Receptors and Ki-67.
Figure 4. Univariate analysis and Forest plots for subgroup analysis of 10-year survival (N = 124). When 
considering the TAZ/CTGF and YAP/CTGF subgroups, analyses were carried out in 115 patients.
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expression of the Hippo transducers TAZ/YAP along with their established target CTGF, and complete data on 
these candidate biomarkers were available for 115 patients32. To our knowledge, this is the first report addressing 
the mevalonate pathway and its connection with established and emerging oncogenic signals in MBC. Overall, 
our data suggest that, on the one hand, HMG-CoAR acts in different oncogenic networks and, on the other hand, 
its expression might represent a favorable prognostic indicator in MBC, similar to earlier reports in FBC18–20.
This study has some limitations. In interpreting our results, it is worth mentioning that we tested the impact 
of HMG-CoAR on survival outcomes that also included cancer-unrelated events. This is due to lack of complete 
information pertinent to the cause of death (deaths: 38; MBC-related deaths: 13 (34.2%); deaths from unknown 
cause: 25 (65.8%), as well as detailed information on adjuvant therapy. In a greater detail, 8 MBC-related deaths 
were recorded in the HMG-CoAR-positive group and 5 in the HMG-CoAR-negative group (Chi2 p = 0.762). 
When considering deaths from any cause, 20 events were recorded in the HMG-CoAR-positive group and 18 
in the HMG-CoAR-negative group (Chi2 p = 0.048). Nevertheless, the use of intermediate time-points (e.g. 
5- and 10-year survival) in a disease characterized by a long natural history, comparable to that of luminal-type 
FBC14, may mitigate the partial unavailability of cancer-specific events. Second, nodal involvement was not con-
sidered in the uni- and multivariate models given that, despite our best efforts, this information was retrieved 
only for 91 patients. In this subset, HMG-CoAR expression was associated with better survival outcomes in the 
node-positive disease. However, given the limited number of patients included in subgroup analyses, presented 
in Figs 4 and 5, these results require further validation in adequately powered studies. It is worth mentioning the 
limited availability of data on adjuvant treatments, which were only available for a restricted number of patients. 
This is extremely common when relying on clinical series, particularly when data and biological samples are 
provided by several participating centers. Nevertheless, it is worth considering that a retrospective study shown 
no benefit from treatment with aromatase inhibitors compared with tamoxifen, which remains the treatment of 
choice in the adjuvant setting for hormone receptor-positive MBC33. Thus, adjuvant therapy for MBC patients, 
which mostly consists in hormone therapies in consideration of the frequent expression of hormone receptors, 
has remained substantially unvaried over the past decades14.
In our opinion, our study provides some interesting insights beyond the suggestion of a prognostic signifi-
cance of HMG-CoAR expression. First, our results place HMG-CoAR in the hormonal network that fuels the 
genesis of MBC, as documented by the significant positive relationship between HMG-CoAR and hormone 
receptor status (ER, PgR, AR). These data open up to a scenario where systemic and local (intratumoral) endo-
crine and metabolic factors participate in recreating a “hormone-rich” background. Three observations explain 
this: i) in FBC, HMG-CoAR expression was positively associated with overweight18, ii) in turn, obesity was 
designed as a risk factor for MBC as a consequence of the age-related increase in both aromatase activity and fat 
mass, which lead to an excess of estrogens11,34–36, and iii) molecular studies documented intratumoral aromatase 
expression and elevated levels of 17β -estradiol in MBC tissues37,38, and both these observations may be connected 
with intratumoral activation of the mevalonate pathway.
In recollecting this evidence, it is plausible that intratumoral HMG-CoAR expression represents an important 
source of hormonal stimuli that drive MBC carcinogenesis and whose activity, both in cancer cells and in other 
tissues39, is enhanced by the underlying metabolic status of these patients (e.g. obesity and related metabolic 
disorders). On this basis, we suggest to carry out extensive metabolic characterization of MBC patients in future 
research that, beyond body mass index, should envision additional tests such as dual-energy X-ray absorptiom-
etry (DEXA) and lipidic profile with 27-hydroxycholesterol (27HC) assessment, as 27HC acts as a selective ER 
modulator inducing proliferation of ER-expressing breast cancer cells40–42. Moreover, considering the connection 
between obesity and MBC, our data support the hypothesis that statins may have anticancer properties, especially 
Figure 5. Univariate analysis and Forest plots for subgroup analysis (node-positive and node-negative) of 
overall, 5-, and 10-year survival (N = 91). 
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in HMG-CoAR-expressing MBC patients. To this end, statins were already found to produce anti-proliferative 
effects (Ki-67 reduction) in a pre-surgical, window-of-opportunity FBC trial, further corroborating the involve-
ment of the mevalonate pathway in hormone-driven breast cancer43.
Next, the positive relationship observed between HMG-CoAR and Hippo transducers provides further 
ground to the preclinically described control on TAZ/YAP operated by the mevalonate pathway. Interestingly, 
while the co-expression of TAZ/YAP and CTGF was previously associated with unfavorable survival outcomes 
in MBC32, HMG-CoAR appeared to be a protective determinant in the TAZ/CTGF- and YAP/CTGF-positive 
backgrounds, as revealed by subgroup analysis. The following, potentially connected, explanations may justify 
these observations. First, beyond metabolic cues, further Hippo regulatory branches supposedly operate in MBC. 
This is not surprising when considering the complexity of Hippo biology and the number of molecular inputs 
that modulate TAZ/YAP activity, such as mechanotransduction, cell density, cell-cell adhesion mechanisms, 
apical-basal polarity factors, hypoxia and the Wnt/β -catenin pathway44. Second, in the subset of MBC with active 
TAZ/YAP-driven transcription, HMG-CoAR expression may delineate a further fraction of tumors at a prevalent 
endocrine-metabolic asset, and be possibly endowed with less aggressive molecular traits.
Our results suggest that HMG-CoAR expression in MBC patients is a potential prognostic marker that 
deserves further attention. Moreover, our findings add a further piece to the biology of MBC, overall linking met-
abolic cues, endocrine stimuli and stem cell pathways. Finally, we would like to encourage investigators engaged 
in MBC research to reconsider survival outcomes in light of history of statin use and HMG-CoAR expression, 
in order to collect preliminary evidence on the therapeutic potential of cholesterol-lowering agents for MBC 
patients.
Material and Methods
Study Participants and procedures. Biological samples from 255 histologically confirmed MBC patients, 
represented on tissue microarrays (TMAs), were immunohistochemically evaluated for the expression of HMG-
CoAR. Eligibility criteria for inclusion were the following: i) complete data on HMG-CoAR, ii) complete data on 
hormone receptors (ER, PgR, AR), and iii) availability of survival data. On this basis, 124 patients were considered 
eligible. The information related to the expression of TAZ, YAP and CTGF was available for 115 patients. The 
biological samples related to patients fulfilling the inclusion criteria were immunostained in 2016. Complete data 
pertinent to post-surgical therapy were not extensively available; in this series adjuvant therapy mostly consisted 
of tamoxifen. Information related to adjuvant therapy was available only for 25 patients, of whom 19 received 
tamoxifen, 5 anastrozole and 1 did not receive any adjuvant treatment. Nodal status was available for 91 patients, 
and this subset was independently analyzed.
TMAs were built from FFPE material, as already detailed13. The immunohistochemical assessment of 
HMG-CoAR was performed in FFPE tissues using the polyclonal antibody anti-HMG-CoAR (HPA008338, 
Sigma-Aldrich, St. Louis, USA) at the dilution of 1:150, as reported in a clinical trial investigating high-dose 
atorvastatin in FBC43.
HMG-CoAR expression was assessed both in terms of staining intensity (0: negative, 1+ : weak, 2+ : moderate, 
3+ : strong) and percentage of cytoplasmic-expressing cells (0–100%). Samples were considered positive if ≥ 30% 
of neoplastic cells exhibited a distinct cytoplasmic immunoreactivity of any intensity. The logic behind the use of 
this cutoff is detailed in the “statistical analysis” section. Immunoreactivity was evaluated independently by two 
investigators (ADB and MM) blinded to treatment outcome. Hormone receptor immunoreactivity was scored 
using the Allred system, and considered positive when > 2. The Allred score (ranging from 0–8) was obtained 
by summing the score assigned to the percentage of tumor-expressing cells (0: No cells positive; 1: ≤ 1% of pos-
itive cells; 2: 1 to 10% of positive cells; 3: 11 to 33% of positive cells; 4: 34 to 66% of positive cells; 5: 67 to 100% 
of positive cells)13,45 and the score assigned to staining intensity (0: negative; 1: weak; 2: intermediate; 3: strong). 
Regarding TAZ, YAP and CTGF, samples were considered to harbor active TAZ/YAP-driven transcription when 
they co-expressed TAZ and CTGF (TAZ/CTGF) or YAP and CTGF (YAP/CTGF)32.
This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the 
Institutional Review Board of the “Regina Elena” National Cancer Institute of Rome and by the Leeds (East) 
Research Ethics Committee (06/Q1205/156). As already specified, informed consent was not required as samples 
were anonymized to the research team13.
Statistical analysis. The Pearson’s Chi-squared test of independence (2-tailed) or the Fisher Exact test were 
used to assess the relationship between categorical variables. The Pearson’s correlation coefficient was used to 
investigate the correlation between HMG-CoAR and the following biomarkers: ER, PgR, AR, TAZ, YAP, and 
CTGF.
Receiver operative characteristics (ROC) curves were used to establish the optimal cut-off values for 
HMG-CoAR in reference to survival outcomes with the highest sensitivity and specificity. The Youden’s index 
was then computed to identify the cut-off values that maximized the difference in sensitivity and specificity 
and detected true-positive and false-positive subjects across the different cut-off points. With this approach, 
HMG-CoAR was considered positive when expressed in ≥ 30% of tumor cells.
OS was calculated as the time from diagnosis to death due to any cause. Five- and 10-year survival were 
calculated as the time from diagnosis to death due to any cause within a 5- and 10-year timeframe, respectively. 
Survival curves were estimated with the Kaplan-Meier method and compared by log-rank test or Tarone-Ware 
test. Uni- and multivariate Cox proportional hazard models were built to identify variables impacting 10-year 
survival, and reported as Hazard Ratios (HR) and 95% Confident Interval (CI). Multivariate models included 
histology, grade, hormone receptor status (ER/PgR), Ki-67 levels and HMG-CoAR expression.
Random hot deck (RHD) imputation was used for the treatment of missing values (histology: 1/124, tumor 
grade: 2/124, Ki-67 levels: 4/124)46. By matching for auxiliary variables (histology, tumor grade, ER, PgR and 
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Ki-67, depending upon the nature of the missing value) pools of donors were identified and a donor was ran-
domly extracted. Then, the value of interest was assigned to the recipient. Statistical tests were two-sided, and p 
values below.05 were considered statistically significant. Statistical analyses were carried out using SPSS software 
(SPSS version 21, SPSS Inc., Chicago, IL, USA).
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